Chemotherapy of Primary and Secondary Hepatic Tumours
Melichar B.
Katedra vnitřních oborů Lékařské fakulty Univerzity Karlovy, Hradec Králové, vedoucí prof. MUDr. J. Malý, CSc., a Klinika onkologie a radioterapie Fakultní nemocnice, Hradec Králové, přednosta MUDr. J. Petera, Ph.D. |
|
Summary:
Liver is the most common site of metastatic disease. Although primary liver tumors are relatively rare in the Czech Republic, liver tumors represent a frequently encountered problem because of high incidence of colorectal and pancreatic cancer. Regimens of systemic chemotherapy or biologic therapy are used for secondary liver tumors according the primary site. It was demonstrated in randomized clinical studies that some of these regimens significantly prolong survival. Although only palliative therapy is possible for most of the patients with liver metastases, resection should be considered in patients with isolated liver involvement. Liver resection represents a curative approach and long-term success seems to be enhanced by neoadjuvant (preoperative) chemotherapy or adjuvant (postoperative) hepatic arterial chemotherapy. Hepatic arterial chemotherapy is also effective in the palliative treatment of unresectable liver metastases. Although fit is still uncertain whether hepatic arterial chemotherapy increases survival of patients compared to systemic chemotherapy, fit may be regarded as the best available treatment in selected patients because of better palliation associated with higher objective response rate and less systemic toxicity. Along with systemic and hepatic arterial chemotherapy, other approaches are being currently investigated in the treatment of primary and secondary liver tumors, including the use of biologic agents, agents with non-cytotoxic mechanistu of action, or chronomodulated chemotherapy.
Key words:
Metastases finto the liver - Primary liver tumours - Liver resection - Non-adjuvant chemotherapy - Adjuvant chemotherapy - Regional Chemotherapy
|